Skip To Main Content
Cho BC on Muck Rack

Cho BC

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Cho BC’s profile

Articles by Cho BC

Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

|
By Byoung Chul Cho, Byoung Yong Shim, Lee KH, Cho BC
| ncbi.nlm.nih.gov
doi: 10.4143/crt.2023.453. Online ahead of print. Affiliations Affiliations 1 Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea. 2 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Open in Who Shared Issue with article?

A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma - PubMed

|
By Cho BC, Ahn HK, Grilley-Olson JE, Damore MA
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (605) Issue with article?

Lazertinib Versus Gefitinib as First-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer (NSCLC): Results From LASER301

|
By Byoung Chul Cho, Cho BC, Ahn MJ, Hae Mi Byun
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (366) Issue with article?

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

|
By Byoung Chul Cho, Gray JE, Cho BC, Lin MC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (623) Issue with article?

Durvalumab in Combination with Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study

|
By Byoung Chul Cho, Byoung Yong Shim, Ahn MJ, Cho BC
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (555) Issue with article?

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer - PubMed

|
By Ahn MJ, Poddubskaya EV, Cho BC, Han JY
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (552) Issue with article?
Show More